Similar to our study, He et al. reported that TIGIT reduces glucose uptake in CD8+ T cells by inhibiting the activity of the AKT/mTOR signaling pathway, thereby damaging the cellular metabolism and effector function in gastric cancer [39]. The gene discussed is AKT1; the disease is gastric cancer.